Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Inflammatory bowel disease (IBD) refers to two chronic autoimmune diseases that cause intestinal inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). In UC, chronic inflammation affects the colon or large intestines, which are synonymous terms. UC usually manifests initially in the terminal part of the colon, the rectum, and is termed ulcerative proctitis. It can extend to the entire left part of the colon (left-sided proctitis) or the entire colon (pancolitis).
GlobalData estimates the 2016 sales for the UC market at approximately $5.4 billion across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Over the course of the 10-year forecast period, the UC market is expected to grow at a Compound Annual Growth Rate (CAGR) of 2.5% across the 7MM. Each of the 7MM are anticipated to grow, recording CAGRs of 2.7%, 1.2%, and 4.3% across the US, 5EU, and Japan, respectively. At the end of 2026, the US will account for 80.4% of sales across the 7MM, while the 5EU and Japan, will account for around 16.1% and 3.4% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of UC in the region, as well as the high annual cost of therapy (ACOT) of J&J’s Stelara and the anticipated ACOT of AbbVie’s risankizumab and Eli Lilly’s mirikizumab in the US market.
Key Questions Answered
How will the UC market landscape in the 7MM (US, France, Germany, Italy, Spain, UK , and Japan) change from 2016–2026?
What are the most promising late-stage pipeline drugs in UC?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the greatest unmet needs in UC? Will the pipeline drugs fulfil these needs of the market?
What are the largest opportunities in the UC landscape?

Scope

Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline UC market revenue from 2016–2026. ACOT and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the UC therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

J&J
AbbVie
Takeda
Roche
Celgene
Galapagos
Shire
Eli Lilly
Pfizer
EA Pharma
InDex Pharma

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ulcerative Colitis: Executive Summary

2.1 Moderate Growth is Expected for UC Market from 2016–2026

2.2 R&D and Corporate Strategies

2.3 Current and Pipeline Products Partially Address Unmet Needs

2.4 Opportunities for Managing Severe to Fulminant Patients Remain

2.5 Oral Therapies and Biosimilars to Drive Growth in UC Market

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Gut Dysbiosis

4.1.2 The Significance of Diet

4.1.3 The Role of Interleukins

4.1.4 Environmental Factors

4.1.5 Epigenetics

4.1.6 Pathophysiology

4.1.7 Biomarkers/Targets of Interest

4.2 Classification or Staging Systems

4.3 Symptoms

4.4 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for UC (2016–2026)

5.5.1 Diagnosed Incident Cases of UC

5.5.2 Age-Specific Incident Cases of UC

5.5.3 Sex-Specific Incident Cases of UC

5.5.4 Diagnosed Incident Cases of UC by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of UC by Severity

5.5.6 Diagnosed Prevalent Cases of UC

5.5.7 Age-Specific Diagnosed Prevalent Cases of UC

5.5.8 Sex-Specific Diagnosed Prevalent Cases of UC

5.5.9 Diagnosed Prevalent Cases of UC by Severity

5.5.10 Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC

5.5.11 Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC

5.5.12 Comorbidities of UC Among the Diagnosed Prevalent Cases of UC

5.5.13 Undiagnosed Prevalent Cases of UC

5.5.14 Total Prevalent Cases of UC

5.5.15 Diagnosed Incident Cases of IC

5.5.16 Diagnosed Prevalent Cases of IC

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis Overview

6.1.1 Diagnosis

6.2 Treatment Overview

6.3 Treatment Guidelines and Leading Prescribed Drugs

6.3.1 Clinical Practice

6.4 US

6.5 5EU

6.6 Japan

7 Competitive Assessment

7.1 Overview

7.2 5-ASAs

7.2.1 Overview

7.2.2 Efficacy

7.2.3 Safety

7.2.4 SWOT Analysis

7.2.5 Forecast

7.3 Steroids

7.3.1 Overview

7.3.2 Efficacy

7.3.3 SWOT Analysis

7.3.4 Forecast

7.4 Thiopurines

7.4.1 Overview

7.4.2 Efficacy

7.4.3 Safety

7.4.4 SWOT Analysis

7.4.5 Forecast

7.5 Other Immunomodulators

7.5.1 Overview

7.5.2 Efficacy

7.5.3 Safety

7.5.4 SWOT Analysis

7.5.5 Forecast

7.6 Remicade

7.6.1 Overview

7.6.2 Efficacy

7.6.3 Safety

7.6.4 SWOT Analysis

7.6.5 Forecast

7.7 Humira

7.7.1 Overview

7.7.2 Efficacy

7.7.3 Safety

7.7.4 SWOT Analysis

7.7.5 Forecast

7.8 Simponi

7.8.1 Overview

7.8.2 Efficacy

7.8.3 Safety

7.8.4 SWOT Analysis

7.8.5 Forecast

7.9 Entyvio

7.9.1 Overview

7.9.2 Efficacy

7.9.3 Safety

7.9.4 SWOT Analysis

7.9.5 Forecast

7.10 Xeljanz

7.10.1 Overview

7.10.2 Efficacy

7.10.3 Safety

7.10.4 SWOT Analysis

7.10.5 Forecast

7.11 Biosimilar Assessment

7.11.1 Introduction

7.11.2 Pricing of Biosimilars Across the 7MM

7.11.3 Uptake of Biosimilars Across the 7MM

7.12 Infliximab Biosimilars

7.12.1 Overview

7.12.2 Efficacy

7.12.3 Safety

7.12.4 SWOT Analysis

7.12.5 Forecast

7.13 Adalimumab Biosimilars

7.13.1 Overview

7.13.2 Efficacy

7.13.3 Safety

7.13.4 SWOT Analysis

7.13.5 Forecast

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Lack of Safe and Efficacious Treatment Alternatives

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Need for Novel Oral Therapies

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Improved Medical Management for Severe to Fulminant Patients

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Cost of Therapy

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Stelara

9.3.1 Overview

9.3.2 Efficacy

9.3.3 Safety

9.3.4 Dosing and Formulation

9.3.5 Potential Clinical and Commercial Positioning

9.3.6 SWOT Analysis

9.3.7 Forecast

9.4 Etrolizumab

9.4.1 Overview

9.4.2 Efficacy

9.4.3 Safety

9.4.4 Dosing and Formulation

9.4.5 Potential Clinical and Commercial Positioning

9.4.6 SWOT Analysis

9.4.7 Forecast

9.5 Ozanimod Hydrochloride

9.5.1 Overview

9.5.2 Efficacy

9.5.3 Safety

9.5.4 Dosing and Formulation

9.5.5 Potential Clinical and Commercial Positioning

9.5.6 SWOT Analysis

9.5.7 Forecast

9.6 Carotegrast (AJM300)

9.6.1 Overview

9.6.2 Efficacy

9.6.3 Safety

9.6.4 Dosing and Formulation

9.6.5 Potential Clinical and Commercial Positioning

9.6.6 SWOT Analysis

9.6.7 Forecast

9.7 SHP-647

9.7.1 Overview

9.7.2 Efficacy

9.7.3 Safety

9.7.4 Dosing and Formulation

9.7.5 Potential Clinical and Commercial Positioning

9.7.6 SWOT Analysis

9.7.7 Forecast

9.8 Upadacitinib Tartrate

9.8.1 Overview

9.8.2 Efficacy

9.8.3 Safety

9.8.4 Dosing and Formulation

9.8.5 Potential Clinical and Commercial Positioning

9.8.6 SWOT Analysis

9.8.7 Forecast

9.9 Filgotinib

9.9.1 Overview

9.9.2 Efficacy

9.9.3 Safety

9.9.4 Dosing and Formulation

9.9.5 Potential Clinical and Commercial Positioning

9.9.6 SWOT Analysis

9.9.7 Forecast

9.10 Kappaproct

9.10.1 Overview

9.10.2 Efficacy

9.10.3 Safety

9.10.4 Dosing and Formulation

9.10.5 SWOT Analysis

9.11 Risankizumab

9.11.1 Overview

9.11.2 Efficacy

9.11.3 Safety

9.11.4 Dosing and Formulation

9.11.5 Potential Clinical and Commercial Positioning

9.11.6 SWOT Analysis

9.11.7 Forecast

9.12 Mirikizumab

9.12.1 Overview

9.12.2 Efficacy

9.12.3 Safety

9.12.4 Dosing and Formulation

9.12.5 Potential Clinical and Commercial Positioning

9.12.6 SWOT Analysis

9.12.7 Forecast

9.13 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Johnson & Johnson

10.3.1 Overview

10.3.2 Portfolio Assessment

10.3.3 SWOT Analysis

10.4 AbbVie

10.4.1 Overview

10.4.2 Portfolio Assessment

10.4.3 SWOT Analysis

10.5 Takeda Pharmaceuticals

10.5.1 Overview

10.5.2 Portfolio Assessment

10.5.3 SWOT Analysis

10.6 Pfizer

10.6.1 Overview

10.6.2 Portfolio Assessment

10.6.3 SWOT Analysis

10.7 Roche

10.7.1 Overview

10.7.2 Portfolio Assessment

10.7.3 SWOT Analysis

10.8 InDex Pharmaceuticals

10.8.1 Overview

10.8.2 Portfolio Assessment

10.8.3 SWOT Analysis

10.9 Celgene Corporation

10.9.1 Overview

10.9.2 Portfolio Assessment

10.9.3 SWOT Analysis

10.10 EA Pharma

10.10.1 Overview

10.10.2 Portfolio Assessment

10.10.3 SWOT Analysis

10.11 Galapagos

10.11.1 Overview

10.11.2 Portfolio Assessment

10.11.3 SWOT Analysis

10.12 Eli Lilly

10.12.1 Overview

10.12.2 Portfolio Assessment

10.12.3 SWOT Analysis

10.13 Shire

10.13.1 Overview

10.13.2 Portfolio Assessment

10.13.3 SWOT Analysis

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.1.1 Epidemiology Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Patient Segmentation

12.3.4 Percent Drug-Treated Patients

12.3.5 Drugs Included in Each Therapeutic Class

12.3.6 Launch and Patent Expiry Dates

12.3.7 General Pricing Assumptions

12.3.8 Individual Drug Assumptions

12.3.9 Generic Erosion

12.3.10 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Ulcerative Colitis: Key Metrics in the 7MM

Table 2: Truelove and Witts Categorization of Disease Severity and Clinical Parameters

Table 3: Montreal Classification for the Distribution of UC

Table 4: Typical Symptoms of UC

Table 5: Risk Factors and Comorbidities for UC and IBD

Table 6: Truelove and Witts Categorization of Disease Severity and Clinical Parameters

Table 7: Different Guidelines Used for Managing UC

Table 8: Country Profile – US

Table 9: Country Profile – 5EU

Table 10: Country Profile – Japan

Table 11: Leading Treatments for UC, 2017

Table 12: Product Profile – Pentasa

Table 13: Efficacy of Different Drugs in the 5-ASA Class in Inducing Remission in UC Patients

Table 14: Efficacy of Different Drugs in the 5-ASA Class in Preventing Disease Relapse in UC Patients

Table 15: Percentage of Patients Experiencing AEs with 5-ASAs

Table 16: 5-ASA SWOT Analysis, 2018

Table 17: Product Profile – Uceris

Table 18: Efficacy of Uceris

Table 19: Uceris SWOT Analysis, 2018

Table 20: Product Profile – AZA

Table 21: Percentage of Patients Experiencing AEs with AZA and 6-MP Therapy

Table 22: AZA SWOT Analysis, 2018

Table 23: Product Profile – MTX

Table 24: MTX SWOT Analysis, 2018

Table 25: Product Profile – Remicade

Table 26: Efficacy Data for the ACT 1 and ACT 2 Trials

Table 27: Safety of Remicade

Table 28: Remicade SWOT Analysis, 2018

Table 29: Product Profile – Humira

Table 30: Efficacy of Humira – Primary and Secondary

Table 31: Humira SWOT Analysis, 2018

Table 32: Product Profile – Simponi

Table 33: Efficacy of Simponi

Table 34: Safety of Simponi

Table 35: Simponi SWOT Analysis, 2018

Table 36: Product Profile – Entyvio

Table 37: Efficacy of Entyvio

Table 38: Efficacy of Entyvio

Table 39: Safety of Entyvio

Table 40: Entyvio SWOT Analysis, 2018

Table 41: Product Profile – Xeljanz

Table 42: Mean change in Mayo score from OCTAVE Sustain

Table 43: Safety analysis from OCTAVE Induction 1 and 2 Trials

Table 44: Rates of various AEs from OCTAVE Induction 1 and 2

Table 45: Xeljanz SWOT Analysis, 2018

Table 46: Marketed and Pipeline Biosimilars for UC, 2018

Table 47: Average price of Remicade discount accross the 7MM

Table 48: Product Profile – Inflectra/Remsima

Table 49: Infliximab Biosimilars SWOT Analysis, 2018

Table 50: Product Profile – Amjevita

Table 51: Adalimumab Biosimilars SWOT Analysis, 2018

Table 52: Unmet Need and Opportunity in UC, 2017

Table 53: Product Profile – Stelara

Table 54: Stelara SWOT Analysis, 2018

Table 55: Product Profile – Etrolizumab

Table 56: Efficacy Data for Etrolizumab

Table 57: Etrolizumab SWOT Analysis, 2018

Table 58: Product Profile – Ozanimod Hydrochloride

Table 59: Efficacy Analysis of Ozanimod Hydrochloride from the Phase II TOUCHSTONE Trial

Table 60: Summary of the AEs Associated with Ozanimod Use in the TOUCHSTONE Phase ll Trial.

Table 61: Ozanimod SWOT Analysis, 2018

Table 62: Product Profile – Carotegrast

Table 63: Efficacy Analysis of Carotegrast

Table 64: AEs Seen in Patients Treated with Carotegrast and Placebo

Table 65: Carotegrast SWOT Analysis, 2018

Table 66: Product Profile – SHP-647

Table 67: SHP-647 – Remission, Response, and Mucosal Healing Rates at Week 12 with Local Endoscopy Readings

Table 68: SHP-647 SWOT Analysis, 2018

Table 69: Product Profile – Upadacitinib

Table 70: Upadacitinib SWOT Analysis, 2018

Table 71: Product Profile – Filgotinib

Table 72: Filgotinib SWOT Analysis, 2018

Table 73: Product Profile – Kappaproct

Table 74: Safety Data for Kappaproct

Table 75: Kappaproct SWOT Analysis, 2018

Table 76: Product Profile – Risankizumab

Table 77: Phase II Safety Data for Risankizumab in CD

Table 78: Risankizumab SWOT Analysis, 2018

Table 79: Product Profile – Mirikizumab

Table 80: Mirikizumab SWOT Analysis, 2018

Table 81: Drugs in Development for UC, 2018

Table 82: 7MM, Key Companies in the UC Market, 2018

Table 83: J&J’s Disease Portfolio Assessment, 2018

Table 84: J&J SWOT Analysis, 2018

Table 85: AbbVie’s Disease Portfolio Assessment, 2018

Table 86: AbbVie’s SWOT Analysis, 2018

Table 87: Takeda’s Disease Portfolio Assessment, 2018

Table 88: Takeda’s SWOT Analysis, 2018

Table 89: Pfizer’s Disease Portfolio Assessment, 2018

Table 90: Pfizer SWOT Analysis, 2018

Table 91: Roche’s Disease Portfolio Assessment, 2018

Table 92: Roche SWOT Analysis, 2018

Table 93: InDex’s Disease Portfolio Assessment, 2018

Table 94: InDex SWOT Analysis, 2018

Table 95: Celgene’s Disease Portfolio Assessment, 2018

Table 96: Celgene SWOT Analysis, 2018

Table 97: EA Pharma’s Disease Portfolio Assessment, 2018

Table 98: EA Pharma SWOT Analysis, 2018

Table 99: Galapagos’ Disease Portfolio Assessment, 2018

Table 100: Galapagos SWOT Analysis, 2018

Table 101: Eli Lilly’s Disease Portfolio Assessment, 2018

Table 102: Eli Lilly SWOT Analysis, 2018

Table 103: Shire’s Disease Portfolio Assessment, 2018

Table 104: Shire SWOT Analysis, 2018

Table 105: UC Market – Global Drivers and Barriers, 2016–2026

Table 106: Key Events Impacting Sales for UC in the US, 2016–2026

Table 107: UC Market – Global Drivers and Barriers in the US, 2016–2026

Table 108: Key Events Impacting Sales for UC in the 5EU, 2016–2026

Table 109: UC Market – Global Drivers and Barriers in the 5EU, 2016–2026

Table 110: Key Events Impacting Sales for UC in Japan, 2016–2026

Table 111: UC Market – Global Drivers and Barriers in Japan, 2016–2026

Table 112: Key Historical and Projected Launch Dates for UC

Table 113: Key Historical and Projected Patent Expiry Dates for UC

Table 114: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for UC, 2016 and 2026

Figure 2: Company Portfolio Gap Analysis in UC, 2016–2026

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC, 2016–2026

Figure 4: Cellular Mechanisms Involved in the Pathogenesis of UC

Figure 5: Types of UC

Figure 6: 7MM, Age-Standardized Diagnosed Incidence of UC (Cases per 100,000 Population), All Ages, Both Sexes, N, 2016

Figure 7: 7MM, Age-Standardized Diagnosed Prevalence of UC (%), All Ages, Both Sexes, N, 2016

Figure 8: 7MM, Sources Used, Diagnosed Incident Cases of UC

Figure 9: 7MM, Sources Used, Diagnosed Prevalent Cases of UC

Figure 10: 7MM, Sources Used, Undiagnosed Prevalent Cases of UC

Figure 11: 7MM, Sources Used, Total Prevalent Cases of UC

Figure 12: 7MM, Sources Used, Diagnosed Incident Cases of UC by Stage at Diagnosis

Figure 13: 7MM, Sources Used, Diagnosed Incident Cases of UC by Severity

Figure 14: 7MM, Sources Used, Diagnosed Prevalent Cases of UC by Severity

Figure 15: 7MM, Sources Used, Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC

Figure 16: 7MM, Sources Used, UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management

Figure 17: 7MM, Sources Used, Diagnosed Incident Cases of IC

Figure 18: 7MM, Sources Used, Diagnosed Prevalent Cases of IC

Figure 19: Diagnosed Incident Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 20: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N, 2016

Figure 21: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N, 2016

Figure 22: 7MM, Diagnosed Incident Cases of UC Segmented by Stage at Diagnosis, Both Sexes, All Ages, N, 2016

Figure 23: 7MM, Diagnosed Incident Cases of UC Segmented by Severity, Both Sexes, All ages, N, 2016

Figure 24: Diagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 25: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N, 2016

Figure 26: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N, 2016

Figure 27: 7MM, Diagnosed Prevalent Cases of UC by Severity, Both Sexes, ≥18 Years, N, 2016

Figure 28: 7MM, Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016

Figure 29: 7MM, Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016

Figure 30: 7MM, Comorbidities Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016

Figure 31: Undiagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 32: Total Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 33: Diagnosed Incident Cases of IC, 7MM, Men and Women, All Ages, 2016

Figure 34: Diagnosed Prevalent Cases of IC, 7MM, Men and Women, All Ages, 2016

Figure 35: UC Treatment Algorithm

Figure 36: Unmet Need and Opportunity in UC, 2018

Figure 37: Overview of the Development Pipeline in UC

Figure 38: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for UC in the 7MM During the Forecast Period

Figure 39: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period

Figure 40: Global Sales of Branded Products for UC by Company in 2016 and 2026

Figure 41: Company Portfolio Gap Analysis in UC During the Forecast Period

Figure 42: Global (7MM) Sales Forecast by Country for UC, 2016 and 2026

Figure 43: Sales Forecast by Class for UC in the US, 2016 and 2026

Frequently asked questions

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026 in real time.

  • Access a live Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.